EMA Authorised: Vyvgart (efgartigimod alfa) — Argenx

View source ↗

Summary

The European Medicines Agency has authorised Vyvgart (efgartigimod alfa) for the treatment of myasthenia gravis and chronic inflammatory demyelinating polyneuro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy
• Myasthenia Gravis

Drugs mentioned

• VYVGART (EFGARTIGIMOD ALFA)

Snippet

Status: Authorised. Therapeutic area: Myasthenia Gravis;Polyradiculoneuropathy, Chronic Inflammatory Demyelinating. MAH: Argenx. Decision date: 11/12/2025. Orphan medicine